Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071384 | 1.00 | KDM1A (0.57) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL31520824 | 1.00 | KDM1A (0.57) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL3206911 | 0.89 | KMT2A (0.54) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL3206908 | 0.89 | KMT2A (0.54) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL25033862 | 0.88 | KMT2A (0.53) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL30441585 | 0.85 | KMT2A (0.58) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL1813191 | 0.84 | KMT2A (0.55) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL6424355 | 0.83 | KMT2A (0.51) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL5694937 | 0.83 | KMT2A (0.58) | KDM1AMAOBKMT2AL3MBTL1AKT1 | |
| SCHEMBL4266530 | 0.83 | KMT2A (0.58) | KDM1AMAOBKMT2AL3MBTL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| WO-2016087975-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-8536172-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536172-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012066065-A1 | PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20110034470-A1 | Inhibitors of JNK | GONG LEYI | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034470-A1 | Inhibitors of JNK | MAPK1, MAP3K6, MAP3K3 | KDM1A 2050/4885MAOB 3462/4885KMT2A 3045/4885 |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | CD38, NQO1, NADK | KDM1A 1257/4885MAOB 494/4885KMT2A 2050/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | KDM1A 1992/4885MAOB 2758/4885KMT2A 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.